"This investment symbolizes Baxter's strong commitment to meeting local needs for critical products and advancing healthcare in China and across the Asia Pacific region," said Peter J. Arduini, president of Baxter's Medication Delivery business. "It also underscores the importance of this key market in Baxter's continuing geographic expansion and growth."
Baxter provides hospitals throughout China with a range of intravenous solutions and specialty products that are used in combination for fluid replenishment, general anesthesia, nutrition therapy, pain management, antibiotic therapy and chemotherapy. The company also serves a growing population of patients within the country with products and services to treat end-stage kidney disease.
In addition to four manufacturing facilities in China, Baxter operates seven others in countries across the Asia Pacific region, including India, Japan, Singapore, Australia and the Philippines.
"In the last year and a half, Baxter has significantly strengthened its regional presence, including the recent opening of the company's new Asia Pacific headquarters in Shanghai," said Gerald Lema, president of Baxter Asia Pacific. "Baxter's new regional focus positions the company well to meet the growing healthcare needs of patients across the region."
Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.
